Damien Kenny1, John F Rhodes2, Gregory A Fleming3, Saibal Kar4, Evan M Zahn4, Julie Vincent5, Girish S Shirali6, Jeremy Gorelick7, Mark A Fogel8, John T Fahey9, Dennis W Kim10, Vasilis C Babaliaros11, Aimee K Armstrong12, Ziyad M Hijazi13. 1. Our Lady's Children's Hospital, Dublin, Ireland. Electronic address: damien_kenny@icloud.com. 2. Miami Children's Health System, Miami, Florida; Duke University School of Medicine, Durham, North Carolina. 3. Duke University School of Medicine, Durham, North Carolina. 4. Cedars-Sinai Medical Center, Los Angeles, California. 5. Morgan Stanley Children's Hospital, New York, New York. 6. Children's Mercy, Kansas City, Missouri. 7. Edwards Lifesciences, Irvine, California. 8. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 9. Yale New Haven Hospital, New Haven, Connecticut. 10. Children's Healthcare of Atlanta, Atlanta, Georgia. 11. Emory University School of Medicine, Atlanta, Georgia. 12. Nationwide Children's Hospital, Columbus, Ohio. 13. Sidra Cardiovascular Center of Excellence, Weill Cornell Medical College, Doha, Qatar.
Abstract
OBJECTIVES: This study provides the 3-year follow-up results of the COMPASSION (Congenital Multicenter Trial of Pulmonic Valve Regurgitation Studying the SAPIEN Transcatheter Heart Valve) trial. Patients with moderate to severe pulmonary regurgitation and/or right ventricular outflow tract conduit obstruction were implanted with the SAPIEN transcatheter heart valve (THV). BACKGROUND: Early safety and efficacy of the Edwards SAPIEN THV in the pulmonary position have been established through a multicenter clinical trial. METHODS: Eligible patients were included if body weight was >35 kg and in situ conduit diameter was ≥16 and ≤24 mm. Adverse events were adjudicated by an independent clinical events committee. Three-year clinical and echocardiographic outcomes were evaluated in these patients. RESULTS: Fifty-seven of the 63 eligible patients were accounted for at the 3-year follow-up visit from a total of 69 implantations in 81 enrolled patients. THV implantation was indicated for pulmonary stenosis (7.6%), regurgitation (12.7%), or both (79.7%). Twenty-two patients (27.8%) underwent implantation of 26-mm valves, and 47 patients received 23-mm valves. Functional improvement in New York Heart Association functional class was observed in 93.5% of patients. Mean peak conduit gradient decreased from 37.5 ± 25.4 to 17.8 ± 12.4 mm Hg (p < 0.001), and mean right ventricular systolic pressure decreased from 59.6 ± 17.7 to 42.9 ± 13.4 mm Hg (p < 0.001). Pulmonary regurgitation was mild or less in 91.1% of patients. Freedom from all-cause mortality at 3 years was 98.4%. Freedom from reintervention was 93.7% and from endocarditis was 97.1% at 3 years. There were no observed stent fractures. CONCLUSIONS: Transcatheter pulmonary valve replacement using the Edwards SAPIEN THV demonstrates excellent valve function and clinical outcomes at 3-year follow-up.
OBJECTIVES: This study provides the 3-year follow-up results of the COMPASSION (Congenital Multicenter Trial of Pulmonic Valve Regurgitation Studying the SAPIEN Transcatheter Heart Valve) trial. Patients with moderate to severe pulmonary regurgitation and/or right ventricular outflow tract conduit obstruction were implanted with the SAPIEN transcatheter heart valve (THV). BACKGROUND: Early safety and efficacy of the Edwards SAPIEN THV in the pulmonary position have been established through a multicenter clinical trial. METHODS: Eligible patients were included if body weight was >35 kg and in situ conduit diameter was ≥16 and ≤24 mm. Adverse events were adjudicated by an independent clinical events committee. Three-year clinical and echocardiographic outcomes were evaluated in these patients. RESULTS: Fifty-seven of the 63 eligible patients were accounted for at the 3-year follow-up visit from a total of 69 implantations in 81 enrolled patients. THV implantation was indicated for pulmonary stenosis (7.6%), regurgitation (12.7%), or both (79.7%). Twenty-two patients (27.8%) underwent implantation of 26-mm valves, and 47 patients received 23-mm valves. Functional improvement in New York Heart Association functional class was observed in 93.5% of patients. Mean peak conduit gradient decreased from 37.5 ± 25.4 to 17.8 ± 12.4 mm Hg (p < 0.001), and mean right ventricular systolic pressure decreased from 59.6 ± 17.7 to 42.9 ± 13.4 mm Hg (p < 0.001). Pulmonary regurgitation was mild or less in 91.1% of patients. Freedom from all-cause mortality at 3 years was 98.4%. Freedom from reintervention was 93.7% and from endocarditis was 97.1% at 3 years. There were no observed stent fractures. CONCLUSIONS: Transcatheter pulmonary valve replacement using the Edwards SAPIEN THV demonstrates excellent valve function and clinical outcomes at 3-year follow-up.
Authors: Barry O'Callaghan; Jenny Zablah; Ryan Leahy; Michael Shorofsky; Joseph Kay; Gareth Morgan Journal: Postepy Kardiol Interwencyjnej Date: 2021-07-09 Impact factor: 1.426
Authors: Bart W Driesen; Evangeline G Warmerdam; Gert-Jan Sieswerda; Folkert J Meijboom; Mirella M C Molenschot; Pieter A Doevendans; Gregor J Krings; Arie P J van Dijk; Michiel Voskuil Journal: Curr Cardiol Rev Date: 2019
Authors: Clara Stammnitz; Dörte Huscher; Ulrike M M Bauer; Aleksandra Urban; Johannes Nordmeyer; Stephan Schubert; Joachim Photiadis; Felix Berger; Sabine Klaassen Journal: J Am Heart Assoc Date: 2022-02-18 Impact factor: 5.501
Authors: Juan Antonio Meca Aguirrezabalaga; Jacobo Silva Guisasola; Rocío Díaz Méndez; Alain Eliott Escalera Veizaga; Daniel Hernández-Vaquero Panizo Journal: Ann Transl Med Date: 2020-08